Last reviewed · How we verify

Neomycin Oral Product

South Australian Health and Medical Research Institute · FDA-approved active Small molecule

Neomycin Oral Product is a Aminoglycoside antibiotic Small molecule drug developed by South Australian Health and Medical Research Institute. It is currently FDA-approved for Pre-operative bowel sterilization, Hepatic encephalopathy (adjunctive therapy), Bacterial gastroenteritis. Also known as: Neo-Fradin.

Neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.

Neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Used for Suppression of intestinal bacterial flora, Hepatic encephalopathy, Traveler's diarrhea prophylaxis.

At a glance

Generic nameNeomycin Oral Product
Also known asNeo-Fradin
SponsorSouth Australian Health and Medical Research Institute
Drug classAminoglycoside antibiotic
TargetBacterial 30S ribosomal subunit
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Neomycin works by irreversibly binding to the bacterial 30S ribosomal subunit, disrupting the translation of mRNA into proteins and ultimately causing bacterial cell death. As an oral formulation, it is poorly absorbed from the gastrointestinal tract and acts locally within the gut, making it useful for reducing intestinal bacterial flora. This mechanism makes it effective for pre-operative bowel sterilization and treatment of certain gastrointestinal infections.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Neomycin Oral Product

What is Neomycin Oral Product?

Neomycin Oral Product is a Aminoglycoside antibiotic drug developed by South Australian Health and Medical Research Institute, indicated for Pre-operative bowel sterilization, Hepatic encephalopathy (adjunctive therapy), Bacterial gastroenteritis.

How does Neomycin Oral Product work?

Neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.

What is Neomycin Oral Product used for?

Neomycin Oral Product is indicated for Pre-operative bowel sterilization, Hepatic encephalopathy (adjunctive therapy), Bacterial gastroenteritis.

Who makes Neomycin Oral Product?

Neomycin Oral Product is developed and marketed by South Australian Health and Medical Research Institute (see full South Australian Health and Medical Research Institute pipeline at /company/south-australian-health-and-medical-research-institute).

Is Neomycin Oral Product also known as anything else?

Neomycin Oral Product is also known as Neo-Fradin.

What drug class is Neomycin Oral Product in?

Neomycin Oral Product belongs to the Aminoglycoside antibiotic class. See all Aminoglycoside antibiotic drugs at /class/aminoglycoside-antibiotic.

What development phase is Neomycin Oral Product in?

Neomycin Oral Product is FDA-approved (marketed).

What are the side effects of Neomycin Oral Product?

Common side effects of Neomycin Oral Product include Nausea, Diarrhea, Vomiting, Abdominal cramping.

What does Neomycin Oral Product target?

Neomycin Oral Product targets Bacterial 30S ribosomal subunit and is a Aminoglycoside antibiotic.

Related